ILF2 and lung carcinoma: On the contrary, docking experiments revealed that the predicted active sites of S. platensis and the ILF2 receptor on the surface of lung carcinoma exhibited the maximum binding affinity, as illustrated in Fig. 7, in comparison to carboplatin at the first active site identified for ILF2.